Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Thomas R Dilling"'
Autor:
José Carlos dos Santos, Martin Schäfer, Ulrike Bauder-Wüst, Barbro Beijer, Matthias Eder, Karin Leotta, Christian Kleist, Jan-Philip Meyer, Thomas R. Dilling, Jason S. Lewis, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
Prostate-specific membrane antigen (PSMA) binding tracers are promising agents for the targeting of prostate tumors. To further optimize the clinically established radiopharmaceutical PSMA-617, novel PSMA ligands for prostate cancer endoradiotherapy
Externí odkaz:
https://doaj.org/article/b5ea39f8dbeb4d3fab741b428d46c1bc
Autor:
Eva M. Stevenson, Adam R. Ward, Ronald Truong, Allison S. Thomas, Szu-Han Huang, Thomas R. Dilling, Sandra Terry, John K. Bui, Talia M. Mota, Ali Danesh, Guinevere Q. Lee, Andrea Gramatica, Pragya Khadka, Winiffer D. Conce Alberto, Rajesh T. Gandhi, Deborah K. McMahon, Christina M. Lalama, Ronald J. Bosch, Bernard Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, R. Brad Jones, for the AIDS Clinical Trials Group A5321 Team
Publikováno v:
JCI Insight, Vol 6, Iss 3 (2021)
Antiretroviral therapies (ARTs) abrogate HIV replication; however, infection persists as long-lived reservoirs of infected cells with integrated proviruses, which reseed replication if ART is interrupted. A central tenet of our current understanding
Externí odkaz:
https://doaj.org/article/fb50f24e6e51492997ce0b7e07385aef
Autor:
Eva M. Stevenson, Adam R. Ward, Thomas R. Dilling, John K. Bui, John Mellors, Rajesh Gandhi, Deborah McMahon, Joseph Eron, Ronald Bosch, Christina Lalama, Joshua Cyktor, Brad Jones
Publikováno v:
Journal of Virus Eradication, Vol 5, Iss , Pp 32- (2019)
Externí odkaz:
https://doaj.org/article/3c238e6e2bb54924bac5f257d41ee792
Autor:
Jason S. Lewis, Nagavarakishore Pillarsetty, Thomas R. Dilling, Maria Davydova, Ian L. Fox, Adam O. Michel, Mike Cornejo, Veronica L. Nagle, Kyeara N. Mack, Kelly E. Henry
Supplementary Materials and Methods. Supplementary Figure 1. Fibroblast isolation from orthotopic PDAC tumor microenvironment. Supplementary Figure 2. Controls for immunofluorescence experiments to confirm no cross-reactivity or non-specific binding,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a066b185f31d6aaf3af1dfcc88dc5d34
https://doi.org/10.1158/1535-7163.22520551.v1
https://doi.org/10.1158/1535-7163.22520551.v1
Autor:
Jason S. Lewis, Nagavarakishore Pillarsetty, Thomas R. Dilling, Maria Davydova, Ian L. Fox, Adam O. Michel, Mike Cornejo, Veronica L. Nagle, Kyeara N. Mack, Kelly E. Henry
Patients with pancreatic ductal adenocarcinoma (PDAC) do not benefit from immune checkpoint blockade (ICB) along the PD-1/PD-L1 axis. Variable PD-L1 expression in PDAC indicates a potential access issue of PD-L1–targeted therapy. To monitor target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8891e60b9376a9e53f82e6eda47b7a41
https://doi.org/10.1158/1535-7163.c.6542677.v1
https://doi.org/10.1158/1535-7163.c.6542677.v1
Autor:
Jason S. Lewis, Michael J. Evans, Ian L. Fox, Jonathan D. Caen, Thomas R. Dilling, Megan M. Dacek, Kelly E. Henry
Supplementary Data file with additional experimental and figures. SUPPLEMENTAL FIGURE 1: Radiolabeling of [89Zr]Zr-transferrin as shown by instant thin layer chromatography. Radiochemical yield ranged from 60-70% and all radiochemical purity was >99%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535ab87705c4fa629a931cb7739139f9
https://doi.org/10.1158/1078-0432.22476051.v1
https://doi.org/10.1158/1078-0432.22476051.v1
Autor:
Jason S. Lewis, John T. Poirier, Brian M. Zeglis, Dalya Abdel-Atti, Thomas R. Dilling, Kimberly J. Edwards, Jacob Pourat, Delphine Vivier, Sebastien Monette, Andrew Chow, Sai Kiran Sharma
A critical benchmark in the development of antibody-based therapeutics is demonstration of efficacy in preclinical mouse models of human disease, many of which rely on immunodeficient mice. However, relatively little is known about how the biology of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108ba06cf20a747a823f9c2f265a424e
https://doi.org/10.1158/0008-5472.c.6509973
https://doi.org/10.1158/0008-5472.c.6509973
Autor:
Cynthia S. Day, Akesh Sinha, Darpan N. Pandya, Jason S. Lewis, Kelly E. Henry, Thaddeus J. Wadas, Yusuf Menda, Thomas R. Dilling, Brandie M. Ehrmann, Nikunj Bhatt, Stephen A. Graves, Veronica L. Nagle
Publikováno v:
Inorganic Chemistry. 59:17473-17487
Over the last three decades, the chemistry of zirconium has facilitated antibody development and the clinical management of disease in the precision medicine era. Scientists have harnessed its reactivity, coordination chemistry, and nuclear chemistry
Autor:
Simon Puttick, Jeroen A.C.M. Goos, Maria Davydova, William S. Price, John F. Quinn, Thomas P. Davis, Abhishek Gupta, Mike Cornejo, Michael R. Whittaker, Jason S. Lewis, Thomas R. Dilling, Andrew Cho
Publikováno v:
Nucl Med Biol
INTRODUCTION: Pretargeting strategies that do not rely on the expression of molecular targets have expanded imaging and therapy options for cancer patients. Nanostars with designed multivalency and which highly accumulate in tumor tissue via the enha
Autor:
Jason S. Lewis, Michael R. Whittaker, Jeroen A.C.M. Goos, Thomas P. Davis, Abhishek Gupta, Simon Puttick, Maria Davydova, William S. Price, Thomas R. Dilling, John F. Quinn, Komal Mandleywala, Lukas M. Carter, Andrew Cho
Publikováno v:
Theranostics
Expression levels of biomarkers are generally unknown at initial diagnosis. The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine